Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Affimed NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AFMD
Nasdaq
8731
https://www.affimed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Affimed NV
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
- Apr 24th, 2024 1:55 pm
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
- Apr 24th, 2024 8:05 am
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Apr 17th, 2024 1:55 pm
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
- Apr 4th, 2024 1:55 pm
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 3:38 pm
Affimed Reports 2023 Financial Results and Operational Progress
- Mar 28th, 2024 10:30 am
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
- Mar 21st, 2024 10:30 am
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
- Mar 14th, 2024 4:00 pm
7 of the Best Speculative Stocks You Can Snag for Less Than $1
- Mar 6th, 2024 8:36 pm
Affimed Announces 1-for-10 Reverse Stock Split
- Mar 6th, 2024 11:30 am
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
- Jan 8th, 2024 9:05 pm
Affimed Announces Leadership Change and Organizational Restructuring
- Jan 8th, 2024 1:00 pm
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
- Jan 3rd, 2024 11:30 am
3 Penny Stocks That Are Too Compelling to Ignore
- Dec 19th, 2023 2:08 pm
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
- Dec 11th, 2023 11:02 am
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
- Dec 11th, 2023 11:00 am
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
- Dec 4th, 2023 11:30 am
Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript
- Nov 20th, 2023 1:51 pm
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Nov 14th, 2023 11:30 am
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
- Nov 9th, 2023 11:30 am
Scroll